SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... MoreBiogen (BIIB) Tops Q1 EPS by $1.40
April 22, 2020 7:04 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $9.14, $1.40 better than the analyst estimate of $7.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.41 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
... More